Samsung Bioepis

  • Expand the footprint with key U.S. stakeholders and increase their understanding and perception of the biosimilar market
  • Enlist a strategic partner with global reach to connect with key stakeholders and target audiences

Collage of articles related to work done with Samsung Bioepis

LHS Solutions

  • Developed a White Paper based on closed expert panel sessions with well-known KOLs
  • Executed LinkedIn Live open forum, featuring topics discussed in white paper
  • Conducted ongoing media relations and corporate visibility/awareness – specifically throughout the U.S. launch of Hadlima

Results

  • Elevation among key stakeholders from FDA officials to key opinion leaders of Samsung’s emerging leadership in the public discourse on the value of biosimilars through the expert panel series, White Paper and two successful open forums
  • Closed expert panels consisted of 17 biosimilar influencers and decision makers from a variety of organizations, including the FDA, American Cancer Research Foundation, Cleveland Clinic, Boston Medical Center and more
  • 590 registrations for open forum event, exceeding goal of 300
  • 1,200+ total views after event aired live
  • Media coverage ongoing including STAT Opinion
  • Continued media relations engagement, emphasizing Samsung Bioepsis as the manufacturer and commitment to safe and effective Biosimilars. Results included original articles in key publications, including Endpoints, Generics Bulletin, Biopharma Dive, BioWorld, Managed Healthcare, Drug Topics, Market Watch and MedCity News, representing 30 placements and five stand alone interviews with journalists

  • All Case Studies